In the field of pharmaceuticals, biosimilars are biological products that are similar or highly similar to the original products and have the same level of efficacy and safety.

The The Drug Controller of India has approved a biosimilar drug for the treatment of auto immune diseases. It is being made by Zydus under the brand name Exemptia. It is similar to the innovative product Humira by AbbVie Chemicals. The drug is Adalimubab. It is indicated in four areas — rheumatoid  arthritis, juvenile idiopathic arthritis, psoriatric arthritis and ankylosing arthritis.The approval is sought for three large indications — Crohn’s disease. ulcerative colitis and plaque psoriasis.Its global sales is estimated to be $12 billion.